Omega-3 Fatty Acids to Combat Sarcopenia

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine how omega-3 fatty acids influence muscle protein metabolism and mitochondrial physiology in the context of human aging.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mayo Clinic

Criteria

Inclusion Criteria:

• Age 18-35 or 65-85 years

Exclusion Criteria:

1. Current use of omega-3 nutritional supplements

2. Fasting plasma glucose ≥126 mg/dL

3. Active coronary artery disease

4. Participation in structured exercise (>3 times per week for 30 minutes or longer)

5. Smoking

6. Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids, tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants)

7. Renal failure (serum creatinine > 1.5mg/dl)

8. Chronic active liver disease (Bilirubin > 17mmol/L, AST>144IU/L, or ALT>165IU/L)

9. Anti-coagulant therapy (warfarin/heparin)

10. INR >3

11. Use of systemic glucocorticoids

12. Chronic use of NSAIDS or aspirin

13. Pregnancy or breastfeeding

14. Alcohol consumption greater than 2 glasses/day

15. Hypothyroidism

16. Fish or shellfish allergy